BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells for the treatment of disc/spine disease and metabolic disorders. The company's lead cell therapy candidate is the BRTX-100, which focuses on providing non-surgical treatment for protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. It also develops the ThermoStem program, a pre-clinical program for the treatment of metabolic diseases, such as type 2 diabetes, obesity, hypertension, and other metabolic disorders, as well as cardiac deficiencies. In addition, the company provides curved needle device, a needle system with a curved inner cannula that allows access to difficult-to-locate regions for the delivery or removal of fluids and other substances. Further, it offers skin care products under the Stem Pearls brand name. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is headquartered in Melville, New York.
Industry, Sector and Symbol
Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Phone631-760-8100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$80,000.00
Profitability
Miscellaneous
Employees9
OptionableNot Optionable
BioRestorative Therapies (OTCMKTS:BRTX) Frequently Asked Questions
What is BioRestorative Therapies' stock symbol?
BioRestorative Therapies trades on the OTCMKTS under the ticker symbol "BRTX."
When is BioRestorative Therapies' next earnings date?
Has BioRestorative Therapies been receiving favorable news coverage?
News articles about BRTX stock have been trending very positive recently, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioRestorative Therapies earned a daily sentiment score of 3.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are some of BioRestorative Therapies' key competitors?
Who are BioRestorative Therapies' key executives?
BioRestorative Therapies' management team includes the folowing people:
- Mr. Mark R. Weinreb, Chairman, CEO & Pres (Age 65)
- Ms. Mandy D. Clyde, VP of Operations & Sec. (Age 36)
- Mr. Francisco J. Silva, VP of R&D (Age 43)
- Mr. Robert Paccasassi, VP of Quality and Compliance
- Dr. Gregory E. Lutz M.D., Chief Medical Advisor for Spine Medicine
How do I buy shares of BioRestorative Therapies?
Shares of BRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioRestorative Therapies' stock price today?
One share of BRTX stock can currently be purchased for approximately $0.6470.
How big of a company is BioRestorative Therapies?
BioRestorative Therapies has a market capitalization of $7.14 million and generates $80,000.00 in revenue each year. BioRestorative Therapies employs 9 workers across the globe.
What is BioRestorative Therapies' official website?
How can I contact BioRestorative Therapies?
BioRestorative Therapies' mailing address is 40 MARCUS DRIVE, MELVILLE NY, 11747. The company can be reached via phone at 631-760-8100 or via email at [email protected]
MarketBeat Community Rating for BioRestorative Therapies (OTCMKTS BRTX)
MarketBeat's community ratings are surveys of what our community members think about BioRestorative Therapies and other stocks. Vote "Outperform" if you believe BRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
